Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quality Improvement PrecivityAD2(TM): A Survey and Clinical Utility Study of the PrecivityAD2 Blood Test in the Evaluation of Cognitive Impairment (QUIP II)

NCT06025877 is registered in ClinicalTrials.gov with C2N Diagnostics as lead sponsor.

NCT NCT06025877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06025877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quality Improvement PrecivityAD2(TM): A Survey and Clinical Utility Study of the PrecivityAD2 Blood Test in the Evaluation of Cognitive Impairment (QUIP II)
Lead sponsor
C2N Diagnostics
Phase
Observational
Overall status
Unknown status
Start date
November 15, 2023
Completion date
April 30, 2025
Enrollment
400 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, cognitive decline, cognitive impairment, dementia, memory impairment, mild cognitive impairment